

## MPOX - CLAIMING GUIDE FOR PRIMARY CARE

27 February 2023

### PURPOSE

This document provides guidance on nationally set fees that can be claimed by primary care providers (general practice and pharmacy), urgent care and afterhours providers to 30 June 2023.

### FEES SCHEDULE

Conditions for claiming include:

- No fee to patient (including general practice/Hauora providers/other co-payments and prescription co-payments).
- No claim for clawback for general practice/Hauora providers/others.
- No simultaneous claiming against any other funding stream.
- All dollar values **exclude GST**.
- Contract funding cancellation will be given in writing with 30 days' notice if prior to 30 June 2023

General Practice/Hauora Providers/Others	Description	Claim
Assessment, Testing, Treatment	In-person assessment, includes testing and prescription (30 minutes)	\$180.00
	Follow up appointments – if positive for MPox (15 minutes)	\$90.00
Urgent Care / Afterhours Care	In-person assessment, includes testing and prescription	\$270.00
Urgent Care / Afterhours Care	Follow up appointment – within 2 weeks of initial assessment related to MPox (15 minutes)	\$135.00

### CLAIMING PROCESS

- Claims should be invoiced as per standard invoicing practice

- Follow-up consultations for management of new and worsening conditions related to confirmed positive MPox test
- Maximum of one consultation per day
- Patient initiated consultation for follow-up

Note: Funding is only available for those who meet eligibility criteria and / or are requested by local Medical Officer of Health

Pharmacy Service	Description	Claim
<b>Dispensing Service</b>	Tecovirimat dispensing in a community pharmacy, including unapproved medicine (section 29) reporting requirements	\$15.00
<b>Delivery Cost</b>	Reimbursement for delivery of a single or multiple medicines as needed.	\$7.00
<b>Prescription Co-Payment</b>	Reimbursement of prescription co-payment per, non-tecovirimat, MPox related treatment	\$4.35

## APPENDIX 1 Pharmacy Service Guidance

### 1. Service components

- 1.1 The Provider must obtain tecovirimat from the pharmaceutical wholesaler approved by Pharmac (currently Healthcare Logistics (HCL)).
- 1.2 If a pharmacy does not have an account with HCL please contact them on 09 969 0736 to arrange an account.
- 1.3 The cost of the tecovirimat is free to the provider including the cost of the medicine and courier to the pharmacy.
- 1.4 Tecovirimat can be ordered from HCL from 31 October 2022.
- 1.5 Tecovirimat should only be ordered upon receipt of a prescription, and not ordered in anticipation of receiving a prescription.
- 1.6 Non tecovirimat MPox treatments

### 2. Service linkages

- 2.1 The Provider must establish and maintain linkages with the local general practices.

### **3. Performance Measures**

- 3.1 The effectiveness of this service will be monitored through data capture in your PhMS and captured in the NZePS.
- 3.2 Tecovirimat is an unapproved medicine. The Provider must work with the supplying pharmaceutical wholesaler to provide the standard unapproved medicine reporting to Medsafe. Further details can be found on the [Medsafe website](#).

#### *Fees, payments, and claiming rules*

### **4. Payment for tecovirimat**

- 4.1 The publicly funded oral antiviral medicines are supplied to the participating pharmacy at zero cost.
- 4.2 Providers will receive payment for the Service through a variation to their COVID Care in the Community Pharmacy agreement with their Te Whatu Ora district
  - (a) dispensing tecovirimat in a community pharmacy fee is \$15 (GST exclusive)
  - (b) delivery fee of tecovirimat \$7.00 (GST exclusive).
  - (c) no simultaneous claiming against any other funding stream
  - (d) funding is only available for those who meet eligibility criteria and / or are requested by the local Medical Officer of Health.
- 4.3 Claims should be invoiced as indicated in your COVID Care in the Community Pharmacy agreement.

### **5. Payment for non-tecovirimat monkeypox treatments**

- a. MPox treatments that are not tecovirimat need to be endorsed 'MPox treatment no co-payment' or similar

### **6. No payment to be sought from Eligible Service Users**

- a. The Provider must not in any circumstances demand or accept any Product Premium, Pharmacy Charge, Co-payment, or any other fee from any Eligible Service User to whom the Provider provides oral MPox antiviral medicines under this service specification.